Juliana Lara Padovani

Juliana Lara Padovani

Auto-generated profile, based on publicly available information

Juliana Lara Padovani

Universidade Estadual Paulista - UNESP, Faculdade de Medicina de Botucatu, Departamento de Anestesiologia, Laboratório GENOTOX, Brazil

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
LZLuciana Bonome Zeminian
Luciana Bonome Zeminian
JPJuliana Lara Padovani
Juliana Lara Padovani
SCSílvia Maria Corvino
Sílvia Maria Corvino
GSGiovanni Faria Silva
Giovanni Faria Silva
MPMaria Inês de Moura Pardini
Maria Inês de Moura Pardini
RGRejane Maria Tommasini Grotto
Rejane Maria Tommasini Grotto
The goal of treatment of chronic hepatitis C is to achieve a sustained virological response, which is defined as exhibiting undetectable hepatitis C virus (HCV) RNA levels in serum following therapy for at least six months. However, the current treatment is only effective in 50% of patients infected with HCV genotype 1, the most prevalent genotype in Brazil. Inhibitors of the serine protease non-structural protein 3 (NS3) have therefore been developed to improve the responses of HCV-infected patients. However, the emergence of drug-resistant variants has been the major obstacle to therapeutic success. The goal of this study was to evaluate the presence of resistance mutations and genetic polymorphisms in the NS3 genomic region of HCV from 37 patients infected with HCV genotype 1 had not been treated with protease inhibitors. Plasma viral RNA was used to amplify and sequence the HCV NS3 gene. The results indicate that the catalytic triad is conserved. A large number of substitutions were observed in codons 153, 40 and 91; the resistant variants T54A, T54S, V55A, R155K and A156T were also detected. This study shows that resistance mutations and genetic polymorphisms are present in the NS3 region of HCV in patients who have not been treated with protease inhibitors, data that are important in determining the efficiency of this new class of drugs in Brazil.

1 October 2019 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
NANayara M. Arruda
Nayara M. Arruda
LBLeandro G. Braz
Leandro G. Braz
FNFlávia R. Nogueira
Flávia R. Nogueira
KSKátina M. Souza
Kátina M. Souza
AAAline G. Aun
Aline G. Aun
MBMariana G. Braz
Mariana G. Braz

1 April 2013 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
JPJuliana Lara Padovani
Juliana Lara Padovani
SCSilvia Maria Corvino
Silvia Maria Corvino
JDJan-Felix Drexler
Jan-Felix Drexler
GSGiovanni Faria Silva
Giovanni Faria Silva
MPMaria Inês de Moura Pardini
Maria Inês de Moura Pardini
RGRejane Maria Tommasini Grotto
Rejane Maria Tommasini Grotto
Key words: HCV; Platelets; CD81

1 September 2019 in Brazilian Journal of Anesthesiology (English Edition)
Verified
Journal Article
Open access
VRValéria Romero
Valéria Romero
JLJuliana Rodrigues Lara
Juliana Rodrigues Lara
Francisco Otero-EspinarFrancisco Otero-Espinar
Francisco Otero-Espinar
MSManoel Henrique Salgado
Manoel Henrique Salgado
NMNorma Sueli Pinheiro Modolo
Norma Sueli Pinheiro Modolo
GBGuilherme Antonio Moreira de Barros
Guilherme Antonio Moreira de Barros
Myofascial pain syndrome is a common cause of musculoskeletal pain. The objective of this study was to evaluate the potential analgesic action of 8% capsaicin cream for topical use in patients with myofascial pain syndrome. Initially, cream formulations of PLA (Placebo) and CPS (Capsaicin 8%) were developed and approved according to the current requirements of the health authority agency. The 40 participating patients were randomly assigned to the PLA and CPS groups in a double-blind fashion. Before the creams were topically administered, according to the allocation group, the local anesthetic was used for a period of 50 minutes directly in the area of interest. The cream was applied to the area of the skin over the trigger point, represented by the area with pain at palpation, in an amount of 10 g for 30 minutes in a circular area of 24 mm diameter. Subsequently, the cream was removed and the skin tolerability parameters were evaluated. The pain was measured before and during the formulation application, as well as at 1 hour, 7 days, 30 days, and 60 days after the procedure, evaluated using a verbal numerical scale (from 0 to 10: with 0 = no pain and 10 = worst pain imaginable). No patient in PLA Group had hyperemia or burning sensation at the site of application, while 85% of patients in CPS Group had hyperemia or burning sensation at 15 minutes. These complaints disappeared 24 hours after the cream was removed. The pain score in CPS Group decreased steadily up to the 60th day of evaluation (p < 0.0001). Application of the formulations did not cause macroscopic acute or chronic skin lesions in patients, and the 8% capsaicin formulation was beneficial and well tolerated.

1 April 2019 in Reproductive Toxicology
Verified
Journal Article
Closed access
MSMaruhen A.D. Silveira
Maruhen A.D. Silveira
JMJoão Paulo C. Marcondes
João Paulo C. Marcondes
JLJuliana R. Lara
Juliana R. Lara
WSWellerson R. Scarano
Wellerson R. Scarano
ICIracema Calderon
Iracema Calderon
DSDaisy Maria Favero Salvadori
Daisy Maria Favero Salvadori

1 August 2016 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
RGRejane Maria Tommasini Grotto
Rejane Maria Tommasini Grotto
NCNatália Mirele Cantão
Natália Mirele Cantão
JPJuliana Lara Padovani
Juliana Lara Padovani
LSLenice Do Rosário de Souza
Lenice Do Rosário de Souza
GSGiovanni Faria Silva
Giovanni Faria Silva
MPMaria Inês de Moura Pardini
Maria Inês de Moura Pardini
Keywords: Hepatitis C vírus; Human platelets antigen polymorphisms; Human immunodeficiency virus